Sensus Healthcare, Inc. (NASDAQ:SRTS) Receives Average Recommendation of “Hold” from Brokerages

Sensus Healthcare, Inc. (NASDAQ:SRTS) has been assigned an average recommendation of “Hold” from the five analysts that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $8.00.

SRTS has been the subject of a number of recent research reports. Zacks Research upgraded Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 22nd. HC Wainwright lowered their price objective on Sensus Healthcare from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, August 12th. Lake Street Capital lowered their price objective on Sensus Healthcare from $13.00 to $6.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Wednesday, October 8th.

Sensus Healthcare Stock Down 2.8%

SRTS opened at $3.10 on Tuesday. The stock has a market cap of $50.96 million, a PE ratio of -51.67 and a beta of 1.38. The business has a 50 day moving average of $3.24 and a 200-day moving average of $4.10. Sensus Healthcare has a 52 week low of $3.03 and a 52 week high of $9.33.

Sensus Healthcare (NASDAQ:SRTS) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.07). The company had revenue of $7.32 million for the quarter, compared to analysts’ expectations of $9.30 million. Sensus Healthcare had a negative net margin of 2.26% and a negative return on equity of 1.58%. Equities analysts anticipate that Sensus Healthcare will post 0.32 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in SRTS. Larson Financial Group LLC bought a new stake in shares of Sensus Healthcare in the 1st quarter worth $26,000. Vise Technologies Inc. bought a new stake in shares of Sensus Healthcare in the 2nd quarter worth $52,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Sensus Healthcare in the 1st quarter worth $71,000. IFP Advisors Inc increased its holdings in shares of Sensus Healthcare by 37.2% in the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company’s stock worth $89,000 after purchasing an additional 5,100 shares in the last quarter. Finally, Trexquant Investment LP bought a new stake in shares of Sensus Healthcare in the 1st quarter worth $93,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.